|
UMBI has many technologies available for licensing:
I. Agricultural and Marine Technologies (Plants, Insects, and Marine Products)
Virus Resistant Transgenic Plants Expressing Disassembly Deficient Viral Coat Proteins
Gene Transfer System for Insects
Subunit Vaccine for Virulent Infectious Bursal Disease Virus
A subunit vaccine for Infectious Pancreatic Necrosis (IPN) in fish
Plants with enhanced pathogen resistance
Land-Based, Self Contained Marine Aquaculture System
II. Imaging (Biophysical Technologies)
Targeted Delivery of Imaging Probes for In Vivo Cellular Imaging
Metal-Enhanced Fluorescence (MEF)
Ultra-fast, highly sensitive Metal-enhanced Chemiluminescence (MEC)
Highly sensitive fluorescence microwave microscope
Novel imaging agents to measure the in vivo concentration of oxygen in the brain using Electron Paramagnetic Resonance (EPR) imaging
III. Therapeutics, Diagnostics and Vaccines (Includes Drug Targets)
Huntington Disease Directly Linked to Perturbation of Mitochondria Function
Radiation Resistant Halophiles
Glycoprotein Synthesis and Remodeling by Enzymatic Transglycosylation
A novel approach for the early diagnosis of prostate cancer
Regulating programmed cell death by activating the autophagic pathway
A Salmonella-based oral vaccine for Anthrax
Antibacterial agent production from marine bacteria, Silicibacter
Surface layer coated biodegradable microcapsules for oral drug delivery
Generation, characterization and isolation of primary human antibody in vitro
Targets for eliminating misfolded proteins that cause human disease (e.g. neurodegenerative diseases)
Antibody assembly on chitosan nanofibers
Novel Therapy for Herpes Virus Infections
IV. Tangible Research Products (Research Tools and Reagents)
RTPCR Kit for Prokaryotic Differential Display
Improved Folding of Recombinant Proteins via Co-expression of Archaeal Chaperones
A New and Efficient Method for Multivalent Peptide Assembly Using Scaffolded Maleimide Clusters
Customizable Helicase Assay Kit
Prion diseases: In vitro conversion assay and applications
Recombinant protein expression using protozoan organisms
UMBI also offers fee for service programs
If you would like additional information on any of the above technologies, to view additional technologies available here at UMBI, or wish to discuss licensing/option terms, please contact:
Jonathan Gottlieb, Ph.D., MBA
Director, Technology Transfer and Commercialization
UMBI Research, Innovation & Commercialization
701 East Pratt Street
Suite 200, Central Administration
Baltimore, Maryland 21202
(240) 314-6506
(410) 385-6331 (f)
gottlieb@umbi.umd.edu
|
